Oncology Drugs

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

A recent FDA approval for a generic cancer drug adds to a growing market, revealing the strategic alliances redefining healthcare access.

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

Stonegate Capital's updated coverage validates AB Science's pivot to ALS and AML, but can its promising clinical assets and shrewd financing de-risk the path forward?

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

With a fresh $31M, Advanced NanoTherapies is advancing a first-of-its-kind dual-drug nanoparticle balloon, a technology poised to disrupt the market.

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

Aethlon Medical's upcoming financial report is more than a balance sheet; it's a test of viability for its revolutionary Hemopurifier blood filter.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

With FDA backing for its novel drug HER-096, a Finnish biotech is advancing a therapy that could finally move beyond symptoms to modify Parkinson's progression.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

AbbVie secures EU approval for AQUIPTA as an acute migraine therapy, creating a dual-use drug that challenges rivals and reshapes patient care strategy.

As Nanobiotix joins Europe's tech elite, its nanotech cancer therapy gains a powerful spotlight, signaling a new era for physics-based medicine.

Early data shows a first-in-class oral drug helps immunotherapy work again in resistant tumors, offering a glimpse of hope where options are running out.

ZYUS secures high-interest debt to stay afloat, but a trading halt and unresolved accounting issues raise serious questions about its long-term resilience.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.